AI Article Synopsis
Article Abstract
Purpose: To investigate the prognostic utility of the cachexia index (CXI) in unresectable advanced gastric cancer (UAGC).
Methods: The relationship between CXI and the outcomes was evaluated in 102 patients with UAGC who had received first-line palliative 5-fluorouracil-based chemotherapy between January 2012 and December 2021.
Results: The median survival time (MST) from first-line chemotherapy initiation was 16.2 months, and the cohort included 60 and 42 patients with high and low CXIs, respectively, based on the optimal CXI cutoff. The rates of patients with a performance status score of 0, recurrence, third-line chemotherapy, and all grade 3-4 side effects, including febrile neutropenia (FN), were significantly higher in the CXI group than in the CXI group. The prognosis based on MST was significantly better in the CXI group than in the CXI group (22.5 vs. 11.6 months, p < 0.001). According to a multivariate analysis, a low CXI and performance status score of 1-2 were poor prognostic factors.
Conclusions: Patients with UAGC and a low CXI had poorer prognoses and more frequent grade 3-4 side effects, including FN, than those with a high CXI. Patients with UAGC and a low CXI should be carefully managed to control for side effects to receive subsequent treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-023-02721-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer.
Sci Rep
October 2024
Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi Abeno-ku, Osaka City, 545-8585, Osaka Prefecture, Japan.
In later-line treatment of metastatic colorectal cancer (mCRC), there may be large differences in treatment efficacy depending on cancer cachexia. Recently, the cachexia index (CXI), which was calculated from the skeletal muscle mass index (SMI), serum albumin concentration, and neutrophil-to-lymphocyte ratio, was developed to evaluate cancer cachexia. We retrospectively examined the CXI of 80 patients who were treated with trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) + bevacizumab (Bmab) therapy as a later-line treatment for mCRC, and assessed the impact of cancer cachexia on chemotherapeutic efficacy using CXI.
View Article and Find Full Text PDFPrognostic value of the fat-free mass index-based cachexia index in patients with colorectal cancer.
Sci Rep
October 2024
Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, No.10, Tie Medical Road, Yangfangdian, Haidian District, Beijing, 100038, China.
Studies have shown that the cachexia index (CXI) is a useful predictor of cachexia in patients with colorectal cancer. However, the application of the CXI is limited stemming from the intricacy and additional cost of radiographic examinations. This study aimed to develop an easy-to-use and practical CXI based on fat-free mass index (FFMI-CXI) to evaluate the prognostic value of FFMI-CXI in CRC.
View Article and Find Full Text PDFThe prognostic impact of perioperative dynamic changes in cachexia index in patients with hepatocellular carcinoma.
Ann Gastroenterol Surg
September 2024
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery The Jikei University School of Medicine Tokyo Japan.
Article Synopsis
- The study investigates the cachexia index (CXI), a measure incorporating skeletal muscle, inflammation, and nutritional status, and its impact on the prognosis of patients with hepatocellular carcinoma (HCC) after liver surgery.
- Researchers analyzed 131 patients who had primary liver resections between 2008 and 2019, assessing preoperative and postoperative CXI to determine its correlation with disease-free and overall survival rates.
- Results indicated that both low preoperative and postoperative CXI levels, along with various clinical factors like tumor characteristics and complications, significantly predicted patient survival, suggesting that monitoring CXI changes could provide valuable prognostic information.
Developing and validating a Modified Cachexia Index to predict the outcomes for colorectal cancer after radical surgery.
Eur J Clin Nutr
October 2024
Department of General Surgery, Nanjing Drum Tower Clinical College of Xuzhou Medical University, Nanjing, Jiangsu, China.
Background: It was reported that the cachexia index (CXI: ) was an essential index for predicting the prognosis of tumor patients. However, since for SMI needs to be measured by CT imaging methods and its calculation was inconvenient. Thus, we developed a modified cachexia index (mCXI: ).
View Article and Find Full Text PDFCachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy.
Cancer Diagn Progn
July 2024
Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Background/aim: Cancer cachexia is associated with poor prognosis in patients with metastatic urothelial carcinoma (mUC). The objective of the study was to assess the cachexia index (CXI), which is a new indicator assessing the status of cancer cachexia, as a prognostic indicator for mUC patients treated with gemcitabine plus cisplatin (GC) chemotherapy.
Patients And Methods: The study included 55 patients with mUC who underwent GC chemotherapy between 2008 and 2022 as first-line chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!